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Abstract:

Introduction:
Mononuclear cells (MNCs) have been shown to increase neovascularization and ulcer
healing after direct injection into the ischemic limbs of patients with unreconstructable
peripheral vascular disease (PVD). Circulating MNCs are composed of lymphocytes (85%),
monocytes (15%) and endothelial progenitor cells (EPCs; 0.03%). It is thought that MNCs
may be effective in ameliorating ischemia since EPCs are a component of the monocyte
fraction, and EPCs have been shown to participate in vascular healing.

We hypothesized that ischemic areas secrete paracrine signals such as cytokines and growth
factors that recruit bone marrow-derived monocytes into the circulation in order to augment
vascular healing. For this reason we predicted that patients with critical limb ischemia (CLI)
undergoing bypass surgery would have elevated preoperative monocyte counts compared to
control subjects without CLI. In addition, since a successful surgical bypass procedure
relieves ischemia, we expected a postoperative decrease in circulating monocyte numbers.

Methods:
We reviewed the records of all patients at the VA Connecticut Healthcare System undergoing
lower extremity peripheral bypass surgery between 2002 and 2007. Patients were excluded if
they did not have both preoperative and postoperative complete blood counts with
differentials within a given time frame. Subjects were divided into two groups: those with
preoperative critical limb ischemia (CLI) and those without. ANOVA and Chi-Square were
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used to compare counts, and multivariable logistic regression was used to determine risk
factors.

Results:
Patients with CLI (n=24) had elevated preoperative monocyte counts compared to control
patients (n=8) undergoing bypass for claudication or asymptomatic popliteal aneurysm
(0.753 ± 0.04 vs. 0.516 ± 0.05; p=0.0046), but the preoperative lymphocyte count was not
significantly different (1.979 ± 0.14 vs. 1.912 ± 0.22; p=0.814). After revascularization,
ischemic patients had decreased monocyte counts compared to control patients (-20% vs.
+55%; p=.0003) although lymphocyte ratios were unchanged in both groups (-10% vs. +1%;
p=0.404). Diabetic patients also had reduced postoperative monocyte counts (-32% vs.
+13%; p=0.035), however multivariable analysis demonstrated that the only factor that
independently predicted reduced postoperative monocyte count was preoperative critical
limb ischemia (p=0.038).

Conclusions:
Diminished numbers of circulating monocytes correlate with relief of ischemia after surgical
revascularization. Circulating monocytes may be a clinically useful surrogate marker of
circulating stem cells for patients undergoing vascular surgery.
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Introduction and Background:

The introduction is divided into two chapters. The first chapter focuses on endothelial
progenitor cells (EPCs), the newly described bone marrow-derived stem cells for the vascular
system. The second chapter introduces peripheral vascular disease (PVD), and further
describes the relevance of EPCs and mononuclear cells (MNCs) in the context of patients
requiring lower extremity bypass surgery for critical limb ischemia (CLI). Monocytes are
then introduced as a potential clinically-relevant surrogate marker for circulating EPCs.

Chapter I: Endothelial Progenitor Cells (EPCs)

EPC Significance:
EPCs have been shown to participate in vascular healing during both acute injury and chronic
disease. The quantity and quality of circulating EPCs correlate inversely with the severity of
vascular disease; a reduction in number or function of EPCs are significant independent risk
factors for an impaired healing capacity, a dysfunctional endothelium, and progression of
atherosclerosis and vascular disease. EPC therapy has been shown to assist in healing of
cardiac and limb ischemia; this therapy has great potential for improving the quality of life
and longevity of patients with severe cardiovascular and peripheral vascular disease (PVD)
who are not candidates for conventional revascularization procedures. In addition, EPCs can
be used to promote vascular graft patency. This chapter focuses on the characterization of
EPCs, positive and negative regulators of EPCs, the role of EPCs in vascular disease, and the
potential for EPC therapy to ameliorate the sequelae of severe PVD.
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Introduction to EPCs:
The ability of endothelium to repair itself depends on recruitment, proliferation, and
migration of surrounding mature endothelial cells as well as the mobilization and
incorporation of circulating EPCs to the injured region. Recent studies have outlined the
importance of EPCs with respect to atherosclerotic vascular disease, acute vessel injury, and
tissue ischemia. EPCs are thought to promote healing of the endothelial monolayer and
vessel wall primarily through processes of reendothelialization and neovascularization; these
repair mechanisms have been shown to reduce the risk of atherosclerotic disease progression
and minimize the negative sequelae of vessel wall injury and tissue ischemia.

Risk factors such as elevated cholesterol, hypertension, diabetes, smoking, physical inactivity
and advanced age are associated with chronic damage to the endothelial monolayer [1]. In
addition, vessel trauma or ischemia can acutely compromise the integrity of the endothelium
and result in endothelial cell apoptosis [2]. Vascular damage is repaired by two synergistic
mechanisms, mediated by two different cell populations. Repair by local proliferation and
migration of resident mature endothelial cells can repopulate the endothelial layer, but these
cells have a limited capacity for regeneration; they become senescent and insufficient for
proper healing as successive replications result in telomere shortening. Alternatively,
circulating bone-marrow derived EPCs have been shown to migrate towards sites of injury
and ischemia, proliferate, differentiate, and incorporate into injured vessel walls as well as
generate new vessels. This repair mechanism provides a source of healthy endothelium with
longer telomeres and a renewed ability to respond to further vascular damage.
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However, EPCs are also susceptible to senescence and dysfunction; normal aging in the
presence of risk factors for vascular disease can lead to the progressive depletion of marrow
cells that give rise to progenitors necessary for arterial repair [1,3]. EPC obsolescence
implies insufficient circulating number and/or functional capacity of EPCs, and consequently
a potential inability to maintain vascular integrity. In the setting of significant risk factors and
a dysfunctional endothelium, which has a limited capacity to heal acute vessel injury,
compensate for chronic vascular damage, and limit abnormalities in vasoreactivity,
atherosclerotic disease will progress [3].

Pathophysiology of Atherosclerosis:
Endothelial damage results in the release of chemokines and cytokines which initiate the
inflammatory cascade. Some of these paracrine factors promote mobilization of EPCs from
the bone marrow, migration to the peripheral circulation, and homing to sites of injury or
ischemia. This activity is coordinated by complex interactions involving: VEGF (vascular
endothelial growth factor), a growth factor that responds to tissue ischemia, assists in the
recruitment of EPC, promotes new vessel formation, and is correlated with rapid EPC
mobilization after traumatic vascular injury [4]; G-CSF (granulocyte colony stimulating
factor), a growth factor for neutrophils that also mobilizes EPCs from the bone marrow;
MMP-9 (matrix metalloproteinase-9), a type 4 collagenase and gelatinase that cleaves the
extracellular matrix to allow EPC migration; and SDF-1 (stromal cell-derived factor-1), a
chemokine that attracts EPCs to the site of injury.
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Under circumstances where a competent bone marrow is able to produce a sufficient quantity
of functional EPCs, these cells arrive at the site of injury and proliferate, differentiate, and
incorporate into the vessel wall. Vascular healing occurs via reendothelialization and
neovascularization, and with healing, the local inflammatory response resolves. A negative
feedback loop results in termination of cytokine release in the absence of inflammation [1].

If the bone marrow is not competent and produces an insufficient quantity of functional EPCs
in response to the local inflammation at the site of vascular damage, then healing does not
occur. This may result from ineffective recruitment or impaired function of senescent EPCs.
In this setting cytokines continue to be released by local inflammatory cells, causing further
inflammation and tissue damage via a positive feedback loop. The failure of aging organisms
to renew endothelial cells exposed to noxious stimuli leads to endothelial dysfunction,
inflammation, and atherosclerosis [1,3].

EPC Number is Inversely Correlated with Vascular Disease Severity:
Atherosclerosis is the result of chronic chemical or mechanical stresses that cause vascular
damage in the setting of deficient repair mechanisms. It has been shown that the number of
circulating EPCs is a significant independent predictor for the severity of atherosclerosis. Hill
and colleagues measured the number of circulating EPCs in 45 men with a mean age of 50
years having various degrees of cardiovascular risk but no history of cardiovascular disease.
Endothelium-dependent and endothelium-independent vascular function was assessed by
ultrasonography of the brachial artery. Interestingly, the researchers observed a strong
inverse correlation between the number of circulating EPCs and the combined Framingham
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risk score, which predicts a subject’s risk for cardiovascular disease. They also observed a
significant positive correlation between the number of circulating EPCs and brachial artery
endothelial function [5].

Werner and colleagues determined the number of EPCs in 519 patients with
angiographically-proven coronary artery disease (CAD) and evaluated the association
between baseline levels of EPCs and major cardiovascular events after 12 months. After
adjustment for relevant variables, increased levels of EPCs were associated with a reduced
risk of death from cardiovascular causes (hazard ratio 0.31), a first major cardiovascular
event (hazard ratio 0.74), revascularization (hazard ratio 0.77), and hospitalization (hazard
ratio 0.76) [6]. Thus these researchers showed that reduced levels of EPCs were a significant,
independent predictor of poor prognosis even after adjustment for traditional cardiovascular
risk factors and disease activity [7].

Characterization of EPCs: Lineage, Markers, and Abundance:
EPCs are rare bone marrow-derived mononuclear cells (MNCs) that are enriched in the bone
marrow, but may also be found in the mononuclear cell fraction of peripheral blood. These
cells were first isolated and induced to differentiate into endothelial cells in vitro by Asahara
and colleagues in 1997 [8,9]. Asahara and colleagues also noted the capacity for these cells
to contribute to vasculogenesis as well as angiogenesis in the setting of tissue ischemia.
[10,11]. However, many aspects of EPC characterization are currently debated, including
their lineage, markers, and the best methods for isolation and culture.
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During embryonic development the mesodermal layer develops into bone marrow and
resident stem cells, including hematopoietic and mesenchymal stem cells. It is likely that
EPCs are derived from hemangioblasts, the multipotent stem cells that are a common
precursor to hematopoietic stem cells and EPCs; however, EPCs may also be derived directly
from hematopoietic stem cells [12-14]. Alternatively, there is evidence to show that myeloid
cells, which are bone marrow-derived hematopoietic committed progenitor cells, may
transdifferentiate into EPCs [15]. This proposed lineage is shown in Figure 1.

In addition, several other non-hematopoietic stem cell types have been induced to
differentiate into mature endothelial cells. For example, multipotent adult progenitor cells
isolated with mesenchymal stem cells and lacking hematopoietic stem cell markers can be
cultured with VEGF and induced to differentiate into an endothelial phenotype that expresses
endothelial cell markers, functions as a mature endothelial cell in vitro, and contributes to
both wound healing and tumor angiogenesis in vivo [16].

Tissue-resident stem cells may also give rise to endothelial cells under certain conditions. For
example, adult cardiac stem cells have been induced to differentiate into vascular tissues
including vascular smooth muscle cells and endothelial cells. In one important study,
Beltrami and colleagues demonstrated that an injection of clonally expanded tissue-resident
cardiac stem cells into an ischemic heart resulted in regeneration of well-differentiated
myocardium including new vessels and myocytes with the characteristics of young cells [17].

Side population (SP) cells, a heterogeneous cell population identified by a capacity to efflux
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Hoechst-33342 and Rhodamine-123 dyes, are composed of hematopoietic stem cells and
non-hematopoietic organ-specific multipotent stem cells [18]. SP stem cells are able to
acquire the endothelial cell phenotype with VEGF stimulation, or acquire the smooth muscle
cell phenotype with TGF-β1/PDGF-BB stimulation; in addition, SP cells can form branching
vascular-like structures with evidence of both cell types in vitro [19]. Figure 1 shows several
proposed routes for the derivation of endothelial cells from EPCs and other sources.

EPCs have also been defined by their functional capacity to form endothelial cell colonies in
vitro, incorporate acetylated low-density lipoprotein (LDL), and exhibit enhanced endothelial
nitric oxide synthase (eNOS) expression after shear stress exposure [20,21].

EPCs can be further characterized using cell surface markers, as depicted in Figure 1. Most
researchers agree that EPCs express the following markers: CD34, which is present on EPCs,
certain hematopoietic cells, and endothelial cells; vascular endothelial growth factor receptor
2 (VEGF-R2), which is essential for angiogenesis and vasculogenesis in conjunction with its
ligand VEGF; and CD133, which is present on a variety of stem cells. It should be noted that
EPCs in the bone marrow and early circulating EPCs express CD133, but after differentiation
occurs circulating EPCs lose CD133 and gain several other surface markers, including
platelet endothelial cell adhesion molecule (CD31), vascular endothelial cadherin (VE
cadherin) and von Willebrand factor (vWF) [2,22].

Another important cell surface marker is CXCR4, which is the receptor for stromal cellderived factor 1 (SDF-1). In the setting of tissue hypoxia, SDF-1 is upregulated by hypoxia
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inducible factor-1 (HIF-1). The CXCR4/SDF-1 pair is known to be important in
hematopoietic stem cell trafficking, including quiescence, homing to the bone marrow, and
mobilization to sites of vascular injury and ischemia [23]. Of note, interfering with this
receptor-ligand interaction can mobilize hematopoietic stem cells into the circulation by
disrupting the CXCR4/SDF-1 bond that tethers these cells to the bone marrow.

CD133 and CD34 are often used as markers for selection and purification of EPCs since
CD133 is not found on mature endothelial cells, and CD34 is not found on the
undifferentiated stem cells from which EPCs derive [24]. However, there is significant
overlap in terms of cell surface markers. For example, mature endothelial cells which are
shed from the vessel wall may express VEGF-R2, VE cadherin, and CD34. In addition,
certain hematopoietic stem cells may express CD34, CD31, VEGF-R2, and vWF [13].
CD133 is found on bone marrow EPCs and early circulating EPCs, but once in the
circulation, EPCs lose expression of CD133 and gain expression of other less specific cell
surface markers as described above; the specificity of this marker is further compromised
because hematopoietic progenitor cells may also express CD133 [2,25].

The lack of a specific marker that is present on all EPCs implies a technical challenge with
respect to isolating these cells from peripheral blood, and has hampered the development of
an established protocol for isolating these cells. Lack of a specific marker has been cited as a
potential source for conflicting evidence in studies evaluating EPC number [1]. In addition,
the possibility that there may be subpopulations of EPCs having different functional
characteristics and surface markers adds to the complexity of the issue [26]. One
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consequence of this problem is that many of the clinical studies evaluating the therapeutic
effects of EPCs have been performed using bone marrow samples that have not been purified
to exclude other cell types, leading to the possibility that the functional effects ascribed to
EPCs may not be due to these cells alone [13].

Another confounding factor is that other cell types bearing different cell surface markers and
derived from bone marrow, peripheral blood, or other tissues may be precursors to
endothelial cells, making the “true” EPC more elusive. As described above, this is further
complicated by the fact that other stem cell types may be induced to transdifferentiate into
EPCs, including mesenchymal stem cells as well as the SP phenotype of human stem cells
(Figure 1) [9,13].

During steady-state conditions in healthy patients, circulating EPCs comprise approximately
0.01% of peripheral blood cells [13]. It has been repeatedly demonstrated that patients with
chronic vascular disease have even fewer circulating EPCs. The rarity of this cell population
is another factor that makes identification and isolation of these cells for therapy or for
research very challenging.

Regulators of EPC Number and Function:
There are many positive and negative regulators of EPCs. These factors have a quantifiable
effect on EPC quantity and quality, as described in the following studies.
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Negative Regulators:
Aging
Heiss and colleagues evaluated circulating EPC number and function, as well as endothelial
function in 20 aged and young subjects with no major cardiovascular risk factors. They
reported that while older people had impaired endothelial function, there was no significant
difference in the number of circulating EPCs between the two age groups. However, EPCs
from older people had significantly decreased survival, migration, and proliferation rates,
suggesting that the impaired maintenance of the endothelium in older subjects may correlate
with functional EPC deficits rather than total EPC number [27,28].

Normal aging diminishes the potential for mature endothelial cells to participate in effective
vascular repair, resulting in progression of atherosclerosis. Impaired endothelial cell function,
bone marrow senescence, and limited availability or compromised function of circulating
EPCs are all factors that may contribute to decreased reserve for repair of vascular injury
with aging.

Hypercholesterolemia
Hypercholesterolemia is a significant risk factor for atherosclerosis. Rauscher and colleagues
performed an elegant study demonstrating that long-term treatment with bone marrowderived progenitor cells from young non-atherosclerotic ApoE-deficient mice was successful
in preventing atherosclerosis progression in ApoE-deficient recipients despite persistent
hypercholesterolemia. In contrast, treatment with bone marrow cells from older ApoEdeficient mice with atherosclerosis was much less effective. This study demonstrates the role
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of competent EPCs in preventing atherosclerosis, as well as the decreased effectiveness of
senescent EPCs to engraft on recipient arteries in areas at risk for atherosclerotic injury [3].

Diabetes
Fadini and colleagues analyzed the association between type 2 diabetes, peripheral vascular
disease (PVD), and levels of circulating EPCs. These researchers used flow cytometry to
quantify circulating progenitor cells (CD34-positive) and EPCs (CD34-positive and VEGFR2-positive) in 51 diabetic patients and 17 control subjects. They reported that the number of
circulating progenitor cells and EPCs from diabetic patients were reduced by 33% and 40%,
respectively, compared with healthy subjects. An inverse correlation was found between the
number of EPCs and the values of fasting glucose. In addition, they determined that PVD
was associated with a 47% reduction in circulating EPCs, and that EPC number directly
correlated with the ankle-brachial index [29].

In a second study, Fadini and colleagues quantified EPCs by flow cytometry in 127 diabetic
patients with and without peripheral arterial disease (PAD). Diabetic patients with PAD
displayed a 53% reduction in circulating EPCs compared to non-PAD patients, and EPC
levels were negatively correlated with the degree of carotid stenosis and claudication
symptoms. In addition, the proliferative and adhesion capacity of cultured EPCs were
significantly lower in diabetic patients with PAD versus patients without PAD [30].

Tepper and colleagues expanded on these findings and noted that proliferation of diabetic
EPCs relative to control subjects was decreased by 48% (p<0.01) and inversely correlated

18
with patient levels of hemoglobin A1c (p<0.05). In addition, diabetic EPCs demonstrated
decreased adherence and were 2.5 times less likely to participate in tubule formation
compared with controls (p<0.05) [31].

Smoking
Kondo and colleagues examined the effects of chronic smoking and smoking cessation on
EPC levels. Circulating EPCs were quantified by flow cytometry in 14 nonsmokers and 15
smokers. The number of circulating EPCs was reduced in chronic smokers and inversely
correlated with the number of cigarettes smoked. Circulating EPCs increased rapidly after
smoking cessation (p<0.0001) and decreased again after resumption of smoking to a level
similar to that before cessation (p=0.0031), suggesting that EPC levels directly respond to the
effects of smoking [32].

Michaud and colleagues studied peripheral blood EPCs in 15 healthy smokers and 11 agematched nonsmokers. The number of EPCs was significantly reduced in smokers versus
control subjects, and the functional activities of EPCs isolated from smokers were severely
compromised. The proliferative response was reduced by 75% and the migratory response
was reduced by 19% (p<0.05). EPCs from smokers also showed decreased adherence and
diminished capacity to form tubes in a matrigel assay. These researchers also found that
EPCs from smokers had a significant reduction in the expression of the endothelial cellspecific markers (VE-cadherin, VEGF-R2, and vWF) [33].
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Positive Regulators:
Exercise
It is generally accepted that exercise and physical training decrease the risk and severity of
cardiovascular and peripheral vascular disease, but the molecular mechanisms for this
protective effect have been elusive. Laufs and colleagues studied EPCs in mice randomized
to either running wheels or no exercise. Numbers of EPCs circulating in the peripheral blood
of trained mice were enhanced to 267%, 289%, and 280% of control levels after 7, 14, and
28 days, respectively. The researchers identified an exercise-induced nitric oxide-dependent
mechanism which elevated serum levels of VEGF and reduced the rate of apoptosis in
spleen-derived EPCs. In addition, running inhibited neointima formation after carotid artery
injury by 22% and increased neoangiogenesis by 41% compared with control animals [34].

Steiner and colleagues examined the effect of exercise on circulating EPCs in patients with
cardiovascular risk factors and/or coronary artery disease (CAD). Twenty patients with
documented CAD and/or cardiovascular risk factors joined a 12-week supervised running
program. After 12 weeks of exercise there was a significant 2.9-fold increase in circulating
EPCs, which was positively correlated with both the change in flow-mediated vessel dilation
and the increase in nitric oxide synthesis. Interestingly, plasma VEGF levels did not change
in response to exercise [35]. Thus regular exercise training appears to augment the number of
circulating EPCs in patients with cardiovascular risk factors.

Another study by Sandri and colleagues showed that ischemic exercise training in patients
with PAD increased VEGF levels by 310% and the number of EPCs by 440% compared to
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controls. However, subischemic exercise training in patients with PAD or CAD did not
increase VEGF levels or EPC number, but was associated with improved integrative capacity
of progenitor cells to organize into endothelial networks, as well as increased CXCR4
expression [36]. In this study ischemic exercise training increased EPC number and
function, while non-ischemic exercise appeared to improve only EPC function.

Hyperbaric Treatment
EPC trafficking is generally thought to be regulated by hypoxic gradients and induced by
VEGF-mediated increases in bone marrow nitric oxide. Interestingly, Goldstein and
colleagues found that hyperoxia induced by hyperbaric oxygen (HBO2) exposure
paradoxically results in a signaling cascade similar to that induced by tissue hypoxia. In a
hindlimb ischemia animal model, the researchers showed that the wound closure rate for a
wound in the non-ischemic limb did not significantly improve in response to HBO2
treatment, but a wound in the ischemic limb showed a significantly improved healing rate in
the presence of HBO2. The researchers proposed that HBO2 treatment increases EPC
mobilization from the bone marrow, but does not increase homing of EPCs into injured nonischemic tissues [37]. Gallagher and colleagues proposed a mechanism of action; they
showed that HBO2 treatments increase nitric oxide synthase (NOS), which elevates NO in the
blood. NO nitrosylates MMP-9 which cleaves membrane-bound stem cell factor (SCF),
prompting EPC proliferation and migration [38]. Several other studies have also
demonstrated that HBO2 treatment mobilizes EPCs from the bone marrow and stimulates
wound healing coincidently with the accumulation of EPCs in ischemic tissues [37,39].
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Exogenous Drug Therapy
Many studies have investigated the effects of certain drug therapies for inducing recruitment,
migration, proliferation, and incorporation of EPCs into target vascular epithelium. Many
drugs have proven useful in this respect, both in vitro, in animal models, and in human
clinical trials.

Vascular Endothelial Growth Factor (VEGF)
VEGF is a growth factor that is upregulated in hypoxic cells via hypoxia inducible factor-1
(HIF-1), and stimulates release of nitric oxide from endothelial cells. VEGF increases
vascular permeability and exhibits a dose-dependent mitogenic and chemotactic effect on
endothelial cells to promote new vessel formation [40]. VEGF is correlated with rapid but
transient EPC recruitment after traumatic vascular injury [4], but has been tested more
extensively in the context of therapeutic angiogenesis. Initial hindlimb ischemia studies
evaluating VEGF therapy showed an increase in neovascularization and improvement in the
hemodynamic deficit of the animal model [40]. Takeshita and colleagues demonstrated a
significant dose-dependent augmentation in ischemic limb perfusion accompanied by
increased collateral formation after intramuscular administration of VEGF [41].

However, VEGF does not seem to be a magic bullet. The Regional Angiogenesis with
Vascular Endothelial Growth Factor (RAVE) trial was a randomized study of adenoviral
VEGF (AdVEGF) gene transfer for the treatment of PAD. A total of 105 patients with
unilateral exercise-limiting intermittent claudication were randomized to receive low-dose
AdVEGF, high-dose AdVEGF, or placebo, administered as 20 intramuscular injections to the
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index leg in a single session. The change in peak walking time, ankle-brachial index,
claudication onset time, and quality-of-life measures were similar among all three groups at
12 and 26 weeks. In addition, AdVEGF administration was associated with increased
peripheral edema, consistent with its known effect of increasing vascular permeability. The
researchers were forced to conclude that VEGF-based treatment had limited utility since it
was not associated with improved exercise performance or quality of life [42].

Granulocyte Colony Stimulating Factor (G-CSF)
G-CSF, a growth factor for neutrophils, interferes with the CXCR4/SDF-1 receptor-ligand
interaction, mobilizing hematopoietic stem cells into the bloodstream. Degradation of SDF-1
in the bone marrow releases EPCs by disrupting the CXCR4/SDF-1 receptor-ligand
interaction which sequesters these cells in the bone marrow. Upregulation of SDF-1 in
peripheral tissues attracts EPCs from the bone marrow to the periphery, particularly to sites
of tissue hypoxia and HIF-1 expression. In this way the CXCR4/SDF-1 receptor-chemokine
interaction is instrumental for mobilizing and incorporating EPCs to sites of vessel injury and
ischemia.

Takahashi and colleagues found that in rabbits with hindlimb ischemia, circulating EPCs
were augmented after pretreatment with GM-CSF, with a corresponding improvement in
hindlimb neovascularization [43]. However, in a pilot study on STimulation of
ARTeriogenesis (the START Trial), GM-CSF or placebo was delivered subcutaneously to
patients with intermediate to severe intermittent claudication as treatment for PAD. This
randomized controlled trial found no difference in the treatment and placebo groups in terms
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of the primary outcome, walking time, or the secondary outcome, ankle-brachial index [44].

Notably, the CXCR4/SDF-1 interaction has been shown to simultaneously recruit bone
marrow-derived smooth muscle cell progenitors to regions of vessel injury where medial
smooth muscle cells undergoing apoptosis express SDF-1. Smooth muscle cell precursors
may assist in vascular repair; however, this response has also been shown to result in
pathological healing and neointimal hyperplasia [45].

HMG CoA Reductase Inhibitors
Known primarily for their lipid-lowering activity, HMG-CoA reductase inhibitors (statins)
increase neovascularization by increasing circulating EPC number and/or augmenting EPC
function. Vasa and colleagues studied 15 patients with angiographically documented stable
CAD to determine the effect of statin therapy on circulating EPC number. These patients
were prospectively treated with 40 mg of atorvastatin per day for 4 weeks. Statin treatment
was associated with an approximately 1.5-fold increase in the number of circulating EPCs
after one week, followed by sustained increased levels to approximately 3-fold throughout
the 4-week study period [46]. Walter and colleagues demonstrated that statins increased
circulating rat EPCs by 2.5-fold at 4 weeks [47]. Dimmeler and colleagues used a mouse
model to show that statins potently augment EPC differentiation from mononuclear cells and
CD34-positive hematopoietic stem cells isolated from peripheral blood [48].

Interestingly, statins, VEGF, erythropoietin, estrogen, and exercise all exert effects on EPCs
via the PI3K/Akt signal transduction pathway. This observation suggests an essential role for
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Akt in regulating hematopoietic progenitor cell mobilization, which is likely mediated
through the eNOS pathway [49].

EPCs and Peripheral Vascular Disease (PVD):
Most studies evaluating the effectiveness of stem cell therapy have used unpurified bone
marrow containing a combination of EPCs, hematopoietic stem cells, and other cells.
Asahara and colleagues originally described the incorporation of autologous CD34-positive
mononuclear cells into foci of neovascularization in the rabbit hindlimb ischemia model [8].
Kalka and colleagues confirmed these studies using human EPCs transplanted into a nude
mouse model, and found that blood flow recovery and capillary density in the ischemic
hindlimb were markedly improved, and the rate of limb loss was significantly reduced. The
rate of limb necrosis and auto-amputation was reduced by 50% compared to controls [15,50].

Tateishi-Yuyama and colleagues investigated the efficacy of autologous implantation of bone
marrow-derived mononuclear cells (BMCs), including EPCs, into the ischemic limbs of
patients with PAD. Twenty-two patients with bilateral leg ischemia were injected with BMCs
in one leg and peripheral blood-derived mononuclear cells in the other. At four weeks, the
ankle-brachial index was significantly improved in legs injected with BMCs compared with
those injected with peripheral blood-derived mononuclear cells. Similar improvements were
seen for transcutaneous oxygen pressure, rest pain, and pain-free walking time. These
improvements were sustained at 24 weeks. The authors concluded that autologous
implantation of BMCs could be safe and effective for achievement of therapeutic
angiogenesis because of the natural ability of marrow cells to supply EPCs and to secrete
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various angiogenic factors or cytokines [51]. Esato and colleagues demonstrated similar
results in patients with PAD who had failed traditional medical treatment and/or surgical
bypass procedures. After BMC transplantation, patients reported improved subjective
symptoms [52].

Bartsch and colleagues reported early results of the TAM-PAD study (Transplantation of
Autologous Mononuclear bone marrow stem cells in patients with Peripheral Arterial
Disease). This study was designed to evaluate the use of combined intraarterial and
intramuscular bone marrow-derived mononuclear cell (BMC) therapy for patients with
moderate to severe intermittent claudication. They reported that two months after harvesting
and delivering BMCs to the ischemic limb, pain-free walking distance increased 3.7-fold and
the ABI was significantly improved after exercise and at rest [53]. Notably, after 13 months
these positive effects persisted at their improved level [54].

Two additional studies evaluating BMCs in patients with PVD are worth mentioning.
Higashi and colleagues evaluated BMC transplantation and its effect on endothelial
dysfunction. They found that BMC implantation significantly improved the transcutaneous
oxygen pressure, pain-free walking time, and endothelium-dependent vasodilation in patients
with limb ischemia [55]. Lastly, Saigawa and colleagues noted that the clinical effectiveness
of autologous bone marrow implantation, as measured by an improvement in ankle-brachial
index, was strongly correlated with the number of CD34-positive cells delivered to the
ischemic limb [56].
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In contrast to the studies evaluating BMC therapy, Ishida and colleagues used only peripheral
blood-derived mononuclear cells in treating patients with PAD. These cells were mobilized
with G-CSF and then harvested and injected intramuscularly. After four weeks the
researchers observed a significant improvement in ankle-brachial index, healing of ischemic
ulcers, and increased mean maximum walking distance [57].

As a group, these studies suggest that the specific cell type, or the combination of cells and
cytokines, required to generate beneficial healing effects in patients with PAD are still
incompletely understood.

Mononuclear Cells and Graft Patency:
Although studies have not been performed with isolated EPCs, several studies have shown
that some bone marrow-derived stem cells can colonize and epithelialize synthetic and
biological vascular grafts and devices to render the foreign surface less thrombogenic. Shi
and colleagues used a canine bone marrow transplantation model in which the marrow cells
from the donor and recipient are genetically distinct. Between 6 and 8 months after
transplantation, a Dacron graft, made impervious to prevent capillary ingrowth from the
surrounding perigraft tissue, was implanted in the descending thoracic aorta. After 12 weeks
the graft was retrieved, and cells with endothelial morphology were identified by silver
nitrate staining. Using repeat polymorphisms to distinguish between the donor and recipient
DNA, Shi and colleagues observed that only donor alleles were detected in DNA from
positively stained cells on the impervious Dacron graft. These results strongly suggest that a
subset of CD34-positive cells localized in the bone marrow can be mobilized to the
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peripheral circulation and can colonize endothelial flow surfaces of vascular prostheses [20].

In a similar study, Bhattacharya and colleagues demonstrated accelerated endothelialization
on polyethylene terephthalate (PET) grafts treated with enriched CD34-positive autologous
bone marrow cells in a canine model. The authors used composite grafts implanted in the
descending thoracic aorta for 4 weeks. The composite grafts had a 4-cm PET graft in the
center flanked by two 4-cm standard PTFE grafts; the entire composite was coated with
silicone rubber to make it impervious, and the PET segment was shielded from perigraft and
pannus ingrowth. On the day before surgery, 120 mL of bone marrow was aspirated, and the
CD34-positive cells were enriched. During surgery, these cells were mixed with venous
blood and seeded onto the PET segment of composite study grafts; the control grafts were
treated with venous blood only. After harvesting, there was a significant increase in surface
endothelialization on the seeded grafts (approximately 92% vs. 27%) with markedly
increased microvessels in the neointima, graft wall, and external area compared with control
grafts [58].

In humans, Peichev and colleagues found that the neointima formed on the surface of left
ventricular assist devices was colonized with cells expressing the markers CD34, CD133, and
VEGF-R2, consistent with the EPC phenotype [22]. Furthermore, Matsuo and colleagues
showed that senescent EPCs may be a risk factor for in-stent restenosis in a study of 46
patients who underwent coronary stenting. Blood samples were collected at the time of
follow-up coronary angiography after stent placement. Patients (n=16) with in-stent
restenosis, defined as greater than 40% stenosis, had decreased EPC numbers and increased
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senescent cells compared to patients without restenosis (n=30). There was no significant
difference in angiogenic growth factors secreted by EPCs between the two groups. On
multivariate analysis, an increased number of senescent EPCs was the independent factor
associated with in-stent restenosis (odds ratio 1.10) [59].

Shin’oka and colleagues have pioneered the exciting field of tissue-engineered biodegradable
grafts seeded with autologous bone marrow cells for the repair of cardiovascular defects in
children. Previous studies showed that bone marrow cells contribute to the construction of
tissue-engineered vascular autografts (TEVA) in vivo, and since these constructs contain
living cells, they may have the ability to grow, self-repair, and self-remodel. These
characteristics are especially desirable in growing children to decrease the number of
necessary revision surgeries. Biodegradable conduits (n=23) and patches (n=19) were
implanted in children for extracardiac total cavopulmonary connection and congenital heart
defects, respectively. TEVA were only implanted in low pressure (venous or pulmonary
artery) systems. Patients received anticoagulation therapy for 3 to 6 months post-operatively.
Intermediate-term follow-up after a median of 16.7 months showed no complications such as
thrombosis, stenosis, or obstruction of TEVA. There was no evidence of aneurysm formation
or calcification. All tube grafts were patent, and the diameter of the tube grafts increased to
approximately 110% of the implanted size over time. These results show that after
intermediate-term follow-up, TEVA are safe and feasible in pediatric cardiovascular surgery
and have excellent hemodynamic performance, even after cessation of anticoagulation
therapy [60-62]. However, the implications for adult patients with PAD are not yet known.
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EPC Therapy:
EPC therapy refers to an intervention that targets the recruitment, mobilization, proliferation,
and incorporation of EPCs into injured vessels and ischemic tissues with the purpose of
augmenting healing and tissue regeneration in animal models and in patients with severe
vascular disease.

In addition to autologous transplantation of EPCs as described previously, certain factors
may be important in augmenting EPC function and increasing ischemic limb perfusion.
Murohara and colleagues showed a significant role for nitric oxide and endothelial nitric
oxide synthase (eNOS) in revascularization of ischemic limbs using L-arginine dietary
supplementation [49]. Notably Takahashi and colleagues found that the development of
regional ischemia in animal models increased the frequency of circulating EPCs, and that
pretreatment with GM-CSF further increased EPC numbers with a corresponding
improvement in hindlimb neovascularization. These findings indicate that circulating EPCs
may be mobilized endogenously in response to tissue ischemia or exogenously by cytokine
therapy to assist in neovascularization of ischemic tissues [43].

As these therapies become established, three categories of patients may be considered for
therapy with EPCs. The first category includes patients with severe ischemic peripheral
vascular disease, a threatened limb, and no surgical or endovascular options for
reconstruction. The second category includes patients with severe comorbid disease who are
not operative candidates for potential procedures. The third category includes patients with
bypass grafts or stents in place; under these circumstances EPC therapy may improve conduit
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survival by preventing restenosis [15]. However, EPC therapy has the potential to stimulate
neovascularization in tumors, and therefore is not indicated for patients with cancer or at high
risk for acquiring cancer [63,64].

Another important consideration in EPC therapy is the possibility of resultant neointimal
hyperplasia after arterial injury due to the contribution of smooth muscle cells stimulated by
SDF-1. Zernecke and colleagues describe the involvement of local SDF-1alpha and its
receptor CXCR4 in neointimal hyperplasia via recruitment of bone marrow-derived smooth
muscle cell progenitors. After arterial injury, SDF-1alpha is expressed in medial smooth
muscle cells. SDF-1alpha binds to platelets at the site of injury, triggers CXCR4- and Pselectin-dependent arrest of progenitor cells on injured arteries or matrix-adherent platelets,
and preferentially mobilizes and recruits progenitors for neointimal smooth muscle cells [45].

In patients that are selected as candidates for EPC therapy, several methods for augmentation
of EPC number and function exist. Strategies include improving the intrinsic function of a
patient’s native cells, processing of precursor cells, providing allogeneic progenitors, or using
a combination of these approaches.

Most studies evaluating EPC therapy for patients with vascular disease used either unpurified
bone marrow samples or a combination of EPCs, hematopoietic stem cells, and other cells
derived from bone marrow. Thus it is unclear whether EPCs alone are sufficient to repair
vascular injury, or whether other supporting cells or components of the bone marrow are also
necessary for a therapeutic effect. This is a critical point, as introduction of nonessential cells

31
may be associated with aggravation of inflammation and vascular injury, thereby
exacerbating the problem for which the patient seeks treatment [13].

Chapter II: Monocytes and Peripheral Vascular Disease (PVD)

Overview of PVD:
Vascular disease has a very high prevalence and mortality rate in the United States.
According to the Centers for Disease Control and Prevention (CDC), cardiovascular and
cerebrovascular disease are the first and third leading causes of death in the United States,
accounting for approximately 40% of all deaths in 2004. The American Heart Association
analysis of 2004 Heart Disease and Stroke Statistics categorizes coronary artery disease
(CAD), stroke, hypertension, heart failure, and peripheral vascular disease (PVD) as subsets
of Cardiovascular Disease. They estimate that in the United States the total cost of these
diseases, which includes funds spent on healthcare as well as indirect costs associated with
loss of work, will be $432 billion in 2007 [65,66].

These vascular conditions are interrelated due to the fact that vascular disease is often
systemic. Events such as myocardial infarction, stroke, and acute ischemia of the lower
extremities may be a manifestation of the same disease process in different organs or
vascular beds. Since atherosclerosis and other risk factors for PVD also predispose to CAD
and stroke, these patients often have coexistent cardiovascular and cerebrovascular disease.
The Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial
showed that 41.1% of patients with PVD had concurrent CAD or cerebrovascular disease,
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and 8.6% had disease in all three vascular beds [67]. Patients with symptomatic PVD have a
5-year mortality of almost 30% due to cardiovascular and cerebrovascular events, and those
with large-vessel PVD have a relative risk of 5.9 (95% CI) for death from cardiovascular
disease within ten years [68-71].

Peripheral arterial disease (PAD) is a subset of PVD. In the lower extremities, PAD involves
obstruction of blood flow in the major arteries that supply the lower limbs. Atherosclerotic
disease is the most common culprit, leading to stenosis and partial or total occlusion of these
large arteries, resulting in various degrees of ischemia. PAD causes significant morbidity by
adversely affecting mobility, function, and the ability to perform activities of daily living.

The clinical severity of PAD is commonly classified using two different modalities, namely
the ankle-brachial index (ABI) and the Fontaine Stages. The ABI is calculated by dividing
the systolic blood pressure at the ankle by the higher of the two systolic brachial blood
pressures. A normal ABI is approximately 1.0-1.1, and increasing severity of PAD is
associated with decreasing ABI. Fontaine Stages are defined as follows: Stage I is
asymptomatic (ABI approximately 0.8-0.9), Stage IIa corresponds to the presence of mild
claudication and Stage IIb represents moderate to severe claudication (ABI approximately
0.5-0.8, depending on severity of claudication), Stage III corresponds to the presence of
ischemic rest pain (ABI approximately 0.3-0.5), and Stage IV to the presence of tissue loss
(ulceration or gangrene, ABI approximately 0.3-0.5) [72,73]. Notably, patients may have
absent palpable pedal pulses irrespective of the severity of PAD.
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The initial signs of lower extremity PAD (Fontaine Stage I) include trophic changes, where a
chronically diminished blood supply results in thickened skin and toenails, as well as loss of
hair growth on the toes and feet. Patients are usually asymptomatic at this point. Intermittent
claudication is the next stage in severity (Fontaine Stage II), and is the earliest and most
frequent presenting symptom [73]. Patients typically complain of pain in the calf or thigh
muscles upon ambulation, due to the increased demand for oxygen by the working muscles
and the inability of the vessels to increase the supply of blood to the ischemic tissue.
Importantly, intermittent claudication is reproducibly produced by exercise and relieved
within 10 minutes after exercise is discontinued. As the disease progresses in severity
patients may develop rest pain (Fontaine Stage III), which is typically described as a sharp
pain in the foot at rest, most commonly when lying flat in bed at night. This pain is
commonly relieved by dependency, and patients may dangle their feet off the bed for relief.
In the late stages of PAD, tissue hypoperfusion may lead to tissue loss (Fontaine Stage IV),
where the blood supply is insufficient to sustain the basic metabolic requirements of the
distal tissues such that ulceration and gangrene result. Major amputation is eventually
required in more than a third of patients with tissue loss [73]. Patients with rest pain and/or
tissue loss are identified as having critical limb ischemia (CLI) which is an important
predictor of poor prognosis, with a 2-year mortality rate of 31.6% according to a study by
the I.C.A.I. Group (Gruppo di Studio dell'Ischemia Cronica Critica degli Arti Inferiori) [74].

Screening for PAD in the absence of symptoms utilizes the ABI measurement. A resting ABI
of ≤ 0.90 is caused by hemodynamically significant lower extremity arterial stenosis and is
commonly used as a threshold below which a patient is given the diagnosis of PAD. In
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symptomatic individuals, a resting ABI of ≤ 0.90 is approximately 95% sensitive for
detecting angiographically significant PAD and almost 100% specific in identifying healthy
individuals [72]. Interestingly the Edinburgh Artery Study, using duplex scanning, found that
one-third of patients with asymptomatic PAD had complete occlusion of a major artery to the
leg [75]. The Rotterdam Study documented the frequency of intermittent claudication and
PAD in a large study group of 7715 patients. They found that although the frequency of
intermittent claudication was between 1% and 4.6% depending on the age group, the actual
prevalence of PAD (as defined by an ABI of ≤ 0.9) was 16.9% in men and 20.5% in women
over age 55 [76]. The Inter-Society Consensus for the Management of Peripheral Arterial
Disease (TASC II) agreed with this assessment, stating that “For every patient with
symptomatic PAD there are another three to four subjects with PAD who do not meet the
clinical criteria for intermittent claudication” [72].

In addition, the TASC II Consensus notes that although intermittent claudication is an
important finding in many patients with PAD, the presence or absence of this symptom does
not always predict the presence or absence of PAD. This is due to the fact that other disease
processes, such as spinal stenosis, can produce symptoms that mimic intermittent
claudication in a patient without PAD. Additionally, patients with sedentary lifestyles, severe
deconditioning, heart disease or other comorbidities which limit exercise may not report
symptoms of intermittent claudication because they do not ambulate far enough to experience
them [72].
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Since the majority of patients with significant PAD are asymptomatic, and since it is
uncommon to screen an asymptomatic patient, the exact prevalence of PAD is difficult to
estimate [73]. However, studies have suggested that, when defined as an ABI of ≤ 0.9, PAD
has a prevalence of approximately 3% in patients under 60 yrs old to approximately 20% in
patients over 75 yrs old [69,75,77].

PAD is usually diagnosed by history and physical exam alone. A high index of suspicion in
patients with multiple risk factors is recommended, even if the patient does not complain of
lower extremity symptoms. The diagnosis of asymptomatic PAD has little clinical relevance
with respect to the lower extremities, but as a strong marker for future cardiovascular events,
early diagnosis and intervention are an important aspect of preventative treatment [71]. As
alluded to previously, CAD is the most common cause of death in PAD patients, accounting
for 40% to 60% of deaths, with cerebral artery disease accounting for 10% to 20% of deaths,
and only 20% to 30% of patients dying of non-cardiovascular causes [72].

There are many risk factors for PAD, only the most significant of which are presented here.
All of the following data and statistics are derived from the TASC II Consensus. As
suggested previously, the prevalence of symptomatic PAD increases with age, following a
smooth curve from approximately 0.5% in patients 30-34 years old to approximately 6.5% in
patients 70-74 years old. There also seems to be a correlation between PAD and race: an ABI
≤ 0.9 was more common in non-Hispanic blacks (7.8%) than whites (4.4%). The prevalence
is also slightly greater in men than women, and this difference increases with the severity of
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disease: in patients with intermittent claudication the ratio of men to women is between 1:1
and 2:1, but in patients with CLI the ratio increases to 3:1 [72].

Smoking is one of the most significant and longest-known risk factors for PAD, recognized
since 1911 when it was documented that symptoms of intermittent claudication were three
times more common in smokers compared to nonsmokers. Furthermore, smoking has a dosedependent effect on PAD; there is a direct correlation between the number of cigarettes
smoked and the severity of disease. Heavy smokers have a four-fold risk of developing
intermittent claudication compared to nonsmokers, and smoking cessation is associated with
a decline in the incidence of PAD symptoms [72]. The Edinburgh Artery Study found that
the relative risk of intermittent claudication was 3.7 in smokers compared to 3.0 in exsmokers who had abstained for five years [75].

Overall, PAD is twice as common in patients with diabetes that in patients without. The
correlation is impressive: in patients with diabetes, for every 1% increase in hemoglobin
A1c, there is a 26% increase in risk of PAD. The presence of peripheral neuropathy and
decreased resistance to infection in diabetic patients complicates the picture, and the
subsequent need for a major amputation is five to ten times more common in patients with
diabetes than in patients without. Notably, insulin resistance is a risk factor even in patients
without diabetes [72].

Hypertension is associated with all types of vascular disease but does not predict the risk of
developing PAD as highly as smoking or diabetes. Hyperlipidemia, on the other hand, has a
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stronger correlation with PAD. The Framingham Study showed that a fasting cholesterol
level of greater than 270 mg/dL was associated with a doubling of the incidence of
intermittent claudication, but it was the ratio of total to high density lipoprotein (HDL)
cholesterol that was the best predictor of occurrence of PAD. Other factors such as markers
of inflammation, hyperviscosity, hypercoagulable states, and hyperhomocysteinemia may
also be risk factors for a poor prognosis [72].

Treatment options for PAD are aimed at two targets: decreasing the risk factors for
atherosclerosis and improving the lower extremity symptoms of PAD. In all cases except for
acute ischemic events, it is advisable to begin treatment with efforts to decrease the risk
factors associated with atherosclerotic disease, with the intent of reducing the risk of lifethreatening thrombotic events such as myocardial infarction and stroke, as well as improving
the symptoms of limb ischemia. Decreasing risk factors involves lifestyle modification and
pharmacotherapy. A cornerstone of the management for PAD involves smoking cessation.
Other important lifestyle modifications include increased exercise and improved diet. In
addition, a combination of lifestyle modification and pharmacotherapy to control diabetes,
hyperlipidemia, and hypertension is recommended. Administration of an antiplatelet agent
such as aspirin or clopidogrel is now a common practice [72].

For patients with intermittent claudication, exercise rehabilitation has been shown to provide
significant clinical benefit, improving exercise performance and community-based walking
ability. It is interesting to note that the benefits correlate more strongly with supervised vs.
unsupervised programs, with treadmill exercise vs. weight training, with experience of severe
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claudication pain during exercise, and with 6 months or more of training [72]. In addition,
agents such as cilostazol (a phosphodiesterase III inhibitor with vasodilator, metabolic, and
antiplatelet activity) as well as naftidrofuryl (a 5-hydroxytryptamine antagonist which may
improve muscle metabolism) have been shown to improve peak treadmill performance and
quality of life in some studies [72].

As mentioned previously, the trials evaluating the use of VEGF and GM-CSF in patients
with intermittent claudication showed no beneficial effects, so these agents are not
recommended for treatment. To summarize, the RAVE trial randomized patients with
intermittent claudication to receive adenoviral VEGF (AdVEGF) gene transfer or placebo for
the treatment of PAD. The researchers concluded that VEGF-based treatment had limited
utility since it was not associated with improved exercise performance or quality of life [42].
In the START Trial, GM-CSF or placebo was delivered subcutaneously to patients with
intermediate to severe intermittent claudication as treatment for PAD. This randomized
controlled trial found no difference in the treatment and placebo groups in terms of the
primary outcome, walking time, or the secondary outcome, ABI [44].

In severe cases refractory to conservative treatment, where intermittent claudication
interferes significantly with a patient’s lifestyle or work and adversely impacts quality of life,
revascularization surgery may be considered for symptoms of claudication alone.

For patients with critical limb ischemia (CLI), the primary goals of treatment include the
following: relief of ischemic rest pain, healing of ulceration, prevention of limb loss, and
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improvement of patient quality of life, function, and survival. Most patients with CLI will
ultimately require a revascularization procedure. However, some patients with severe
comorbidities or poor predicted post-revascularization outcome in terms of quality of life or
function may be treated with a primary amputation. For patients with CLI who are awaiting a
revascularization procedure, who decline amputation, or who have no surgical options for
reconstruction, pain control with regularly-dosed narcotics is often required. Pressure relief
and antibiotics may assist in ulcer healing. In addition, intermittent IV infusion of
prostanoids (prostaglandin-E1 or iloprost) may help reduce rest pain and heal ischemic
ulcers, though these agents are more commonly used in Japan than in the United States.
Notably, recent trials do not support the benefit of prostanoids in promoting amputation-free
survival [72]. Hyperbaric oxygen therapy may be beneficial in reducing the risk of major
amputation in patients with diabetic foot ulceration according to a Cochrane review, but
methodological issues and the studied populations limit its generalizability to all patients
with CLI [72].

For patients with CLI who are surgical candidates, several options exist. For localized
disease, techniques include percutaneous angioplasty and stenting or open surgical
endarterectomy. The exact distribution and severity of the lesions, as well as individual
patient factors, dictate the recommended intervention. For more extensive disease, open
peripheral bypass procedures are recommended, provided there is an appropriate target vessel
for reconstruction [72]. It is important to note that for patients undergoing angioplasty or
surgery it is necessary to obtain an angiogram to localize and characterize the lesions, and to
identify inflow and outflow vessels as necessary. Angiography requires that a patient have
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acceptable renal function or the option for hemodialysis.

Percutaneous angioplasty and stenting has the distinct advantage that it is minimally invasive
and thus less stressful than an open surgical procedure, making it attractive for patients with
comorbidities and high risk for complications. However, the long-term patency rates are
inferior to that of open surgical procedures. For infrainguinal stenting, the 3-year patency
rates are below 60%; depending on the study quoted, they range from 42% to 72% [73]. As
expected, however, the TASC II Consensus reports that perioperative complication and
mortality rate are superior to those of open surgical procedures [72]. Importantly,
percutaneous angioplasty and stenting interventions have dismal results when used distal to
the knee, so for patients with infrapopliteal disease and CLI, autogenous vein bypass is the
first line of reconstructive therapy [73].

In general, endarterectomy is performed for local disease in patients who are appropriate
candidates, and infrainguinal bypass procedures are performed for more extensive disease.
Notably, patients with CLI tend to have more extensive disease and often require open
bypass reconstruction, provided there is an adequate target vessel. Typically autogenous vein
grafts are used for bypass procedures if they are available and of sufficient caliber. When
using a non-diseased saphenous vein graft of adequate caliber, the patency rate is approx 7080% at 5 years irrespective of whether the vessel is reversed or incorporated in situ. In
patients without an available autologous vein for use as a graft, a prosthetic graft may also be
used. These grafts have better results when the outflow is to the above-knee (AK) popliteal
artery, as patency rates drop sharply when the outflow is infrapopliteal. For this reason the
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use of a native vessel is recommended if the distal anastomosis is below the knee. According
to the TASC Consensus, autologous vein grafts spanning from the femoral to the below-knee
(BK) popliteal artery have a patency rate of approximately 70% at 5 years. In contrast,
prosthetic grafts spanning from the femoral to the BK popliteal artery have a patency rate of
approximately 30% at 5 years [72].

As mentioned previously, the goals of peripheral bypass surgery include resolution of
ischemia, healing of ulcers and wounds, improvement in patient symptoms, function, and
quality of life, and preservation of the extremity. However, bypass grafts are not without
their problems. In patients with preoperative limited healing potential, the risk of
postoperative delayed wound healing and infection are very real. In addition, grafts may
thrombose acutely or after several months or years. Patients must remain on anticoagulation
and must have a high index of suspicion for complication so that if problems arise they can
be treated emergently.

Graft patency is intimately correlated with graft incorporation and the natural healing
process. These processes are different depending on the type of graft; specifically, whether a
native vein or a prosthetic graft is used. During vein graft incorporation there is smooth
muscle infiltration and extracellular matrix deposition as the vein graft adapts to the arterial
environment. In some cases exuberant healing may be pathologic, resulting in neointimal
hyperplasia, vein graft stenosis, and subsequent graft failure. In prosthetic grafts,
incorporation involves the deposition of a layer of endothelial cells on the flow surface of the
grafts, which assists in making the graft less thrombogenic. However, if there is a disruption
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or failure of this process, the graft may become thrombogenic, predisposing to occlusion and
failure [78-80].

Cell-Based Therapy for PVD:
As previously described, mononuclear cells (MNCs) and endothelial progenitor cells (EPCs)
are two populations of cells found in the bone marrow and periphery which are associated
with vascular protection and healing. The circulating MNC fraction consists of
approximately 85% lymphocytes, 15% monocytes, and 0.03% EPCs [13]. EPCs are thought
to assist with reendothelialization and neovascularization in response to acute or chronic
vascular injury; in addition, EPC numbers directly correlate with vascular protection and
healing, and inversely correlate with the severity of vascular disease.

Prior studies have used bone marrow-derived MNCs to increase neovascularization and ulcer
healing by direct injection into the limbs of patients with unreconstructable limb ischemia. In
addition, circulating peripheral MNCs have been investigated with similar beneficial effects.
The protective and healing properties of the MNC fraction have been attributed to EPC
activity; however it is possible that the monocyte component plays an active role in vascular
healing and that monocytes are a clinically-relevant surrogate marker for EPCs.

In summary, Tateishi-Yuyama and colleagues investigated the efficacy of autologous
implantation of bone marrow-derived mononuclear cells (BMCs), including EPCs, into the
ischemic limbs of patients with PAD. At four weeks, they noted significant improvement in
ABI, transcutaneous oxygen pressure, rest pain, and pain-free walking time [51]. Bartsch and
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colleagues reported early results of combined intraarterial and intramuscular BMC therapy
for patients with moderate to severe intermittent claudication. Two months after harvesting
and delivering BMCs to the ischemic limb, pain-free walking distance increased 3.7-fold and
the ABI was significantly improved after exercise and at rest [53]. Notably, after 13 months
these positive effects persisted at their improved level [54]. In addition, Saigawa and
colleagues noted that the clinical effectiveness of autologous bone marrow implantation, as
measured by an improvement in ABI, was strongly correlated with the number of CD34positive cells delivered to the ischemic limb [56]. In contrast to the studies evaluating BMC
therapy, Ishida and colleagues used only peripheral blood mononuclear cells in patients with
PAD. These cells were mobilized with G-CSF and then harvested and injected
intramuscularly. After four weeks the researchers observed a significant improvement in
ABI, healing of ischemic ulcers, and increased mean maximum walking distance [57].

These studies suggest that the specific cell type, or the combination of cells and cytokines,
required to generate beneficial healing effects in patients with PAD are still incompletely
understood. However, the implications of these studies for patients with unreconstructable
lower extremity critical limb ischemia are very exciting. The patients most likely to benefit
from cell-based therapy include those patients with CLI and no surgical or endovascular
options for reconstruction, as well as patients with severe comorbid disease who are not
operative candidates for potential bypass procedures.
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Monocytes and Peripheral Arterial Disease (PAD):
The relationship between monocytes and advanced atherosclerosis is well established, since
monocytes are known to contribute to the foam cells of the lesions. The following key
processes outline the importance of monocytes in the development of atherosclerosis [81]:
1) endothelial injury; 2) intimal cholesterol accumulation and monocyte invasion with
subsequent foam cell formation; 3) migration and proliferation of smooth muscle cells with
expression of extracellular matrix; 4) local thrombus formation with secondary organization;
5) calcification and /or plaque rupture; and 6) final occlusion due to plaque rupture or
thrombus formation [81].

The fact that EPCs are a component of the circulating monocyte fraction adds relevance to
the study of monocytic populations in the setting of vascular disease. However, only a few
studies have specifically addressed circulating monocytes in patients with PAD. Several
studies have shown that patients with PAD have increased inflammatory markers, including
monocyte chemoattractant protein-1 (MCP-1), a paracrine factor which mediates the
recruitment of monocytes. Nylaende and colleagues studied the relationship between
biochemical markers of inflammation and the diagnostic measures of PAD, including ABI,
maximum treadmill walking distance, and angiographic score. In 127 patients with
angiographically verified PAD, MCP-1 and CD40L were independently and significantly
correlated with the angiographic score [82]. A study by Petrkova and colleagues also found
that MCP-1 is elevated in patients with PAD compared to controls [83].

Hoogeveen and colleagues, as part of the Atherosclerosis Risk in Communities study,
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demonstrated that there was a significant association of MCP-1 with PAD, independent of
traditional coronary heart disease risk factors, with an odds ratio of 2.14 (95% CI) for the
highest MCP-1 tertile compared to the lowest. Incident coronary heart disease risk increased
significantly for each standard deviation difference in MCP-1 level, independently of other
cardiovascular risk factors, including inflammatory markers. These data show that MCP-1 is
associated with atherosclerotic disease. [81].

The correlation between PAD and inflammation is known, but what makes these studies
interesting is that MCP-1 has also been associated with angiogenesis. A study by Muhs and
colleagues in 2004 followed up prior observations that local infusion of recombinant MCP-1
could enhance collateral artery formation in rabbit and pig hindlimb models. Owing to the
clinical disadvantages of protein infusion, Muhs and colleagues developed a nonviral,
liposome-based MCP-1 gene transfer in a pig hindlimb ischemia model. Development of
conductance as a measure of functionally relevant collateralization was evaluated in occluded
as well as untreated limbs of each treatment animal and compared to control animals. The
MCP-1 and control liposomes were locally delivered at the time of femoral artery occlusion.
Two weeks after occlusion, collateralization was determined as changes in peripheral
hemodynamic conductance, peripheral over aortic blood pressure ratio, and angiographically
visible morphology of the peripheral vessel tree. Nonviral MCP-1 gene transfer significantly
improved peripheral conductance (MCP-1 = 23.81 ± 2.81% and control = 11.69 ± 2.78%) as
well as the ratio of peripheral over aortic blood pressure (MCP-1 = 0.75 ± 0.02% and control
= 0.64 ± 0.03%) compared to controls [84].
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Another relevant study by Seidler and colleagues reported that intra-arterial infusion of
MCP-1 in a pig model after unilateral femoral artery occlusion stimulated collateral artery
growth. Specifically, infusion of two micrograms per minute of MCP-1 for six hours was
sufficient to double the arterial conductance at two weeks and sustain a significant increase in
arterial conductance after six weeks [85].

These studies suggest that ischemic areas are capable of angiogenesis and are responsive to
monocytes, stimulating a monocyte influx by release of the chemoattractant MCP-1. Since
human patients with PAD and CAD have elevated plasma MCP-1, the connection between
monocytes and relief of ischemia is plausible. However, the preceding studies did not
correlate the levels of MCP-1 or the severity of PAD with numbers of circulating monocytes.
This data would be helpful with respect to the determination of the effector cell.

To our knowledge, there is only one study in the literature that evaluated patients with PAD
and circulating monocyte number. In 2005 Nasir and colleagues reported the results of a
study in 3949 patients followed as part of the National Health and Nutrition Examination
Survey (NHANES). The objective of the study was to assess the independent association of
white blood cell (WBC) types and other inflammatory markers with the presence of reduced
ABI, a marker of subclinical PAD. All subjects had no known vascular disease, and
subclinical PAD was defined as an ABI < 0.9 in at least one leg. The authors found that
elevated monocytes were the only specific WBC type that independently predicted the
presence of atherosclerotic PAD. Even after adjustment for traditional cardiovascular risk
factors, the odds ratio of PAD when comparing the highest to the lowest quartiles was 2.24
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(95% CI). When WBC types and inflammatory markers were simultaneously included in the
full model, the corresponding odds ratio was 1.91 (95% CI). Neutrophil counts, C-reactive
protein (CRP) levels, and fibrinogen levels did not have significant odds ratios. Nasir and
colleagues thus showed that elevated monocytes were significantly and independently
associated with PAD in a representative sample of the U.S. population after adjustment for
other inflammatory markers [86]. Notably, all of these patients had subclinical PAD,
suggesting that even patients with minimal atherosclerosis and no clinical ischemia may
activate the monocyte fraction of the WBC population.

Together these studies suggest that elevated MCP-1 and increased monocyte numbers
correlate with tissue ischemia in patients with PAD. It is plausible that ischemic tissues
release MCP-1 into the bloodstream to recruit monocytes into ischemic areas and promote
vascular healing. Since monocytes and EPCs are components of the mononuclear cell
fraction which has been shown to be responsible for vascular healing in many prior studies,
this healing process may involve EPCs, monocytes, or both. Although this theory explains
many observations, it may further blur the distinction between EPCs and monocytes. On the
other hand, it may also provide a novel and clinically-relevant surrogate marker for
circulating EPCs.

Distinguishing EPCs and Monocytes:
As suggested earlier, the lineage of EPCs is not entirely known. In addition, many types of
cells may be precursors to endothelial cells. Monocytes are closely related to EPCs; they are
thought to be derived from common precursors and to give rise to similar daughter cells. This
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is shown in Figure 1, where it is clear that the lineage of EPCs and monocytes intersect;
however, Figure 1 is an oversimplified representation of EPC and monocyte lineage.

In fact, a very recent study by Sieveking and colleagues isolated and defined different
populations of putative EPCs; they have called them early endothelial progenitor cells (early
EPCs) and late outgrowth endothelial cells (late OECs). Early EPCs, which appear in culture
after 4 to 7 days, are similar to those originally described by Asahara and colleagues [8] and
have been used in therapeutic studies [50]. In contrast, late OECs appear in culture after 14 to
21 days, and form colonies with high proliferation rates. These two different populations
have been classified as EPCs because they both express endothelial markers [87].

Sieveking and colleagues identified these subpopulations by using a novel endothelial cellspecific angiogenesis assay that highlights strikingly different angiogenic properties of
different putative EPCs and permits detailed functional characterization of EPCs. The
researchers found that late OECs, but not early EPCs, form vascular networks in vivo and
incorporate into vascular networks. In contrast, early EPCs, but not late OECs, augment
angiogenesis in a paracrine fashion [87].

According to Sieveking and colleagues, since the differentiated fate of any putative
endothelial progenitor cell is necessarily an endothelial cell, de novo tubulogenesis and
incorporation into established vascular networks are important functional criteria by which
putative EPCs should be assessed. Thus the researchers suggest that early EPCs are not true
progenitors of endothelial cells but a monocytic cell capable of indirectly facilitating
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angiogenesis in a paracrine fashion [87]. Figure 2 shows a proposed lineage diagram for
EPCs that incorporates these new findings.

The results generated by Sieveking and colleagues confirm an important study by Yoder and
colleagues, which reported that early EPCs are cells of low proliferative potential that are
hematopoietic in origin and differentiate into macrophages rather than endothelial cells in
culture [26]. In addition, a study by Yoon and colleagues suggested that the paracrine factors
secreted by the monocytic early EPCs include VEGF and IL-8, and that both early EPCs and
late OECs have receptors for these cytokines [88]. Notably, there was no mention of MCP-1
in any of these studies.

Although the connections are as yet undefined, there is a wide array of literature that suggests
that the interplay between the following three related concepts may be significant: the known
capability of the mononuclear cell fraction, composed of lymphocytes, monocytes, and
EPCs, to participate in vascular healing with clinically relevant effects; the synergistic
relationship between EPCs and monocytes in terms of paracrine stimulation, which
orchestrates incorporation of EPCs and formation of vascular networks; and the evidence that
patients with PAD have higher levels of paracrine factors (MCP-1) and greater numbers of
circulating monocytes than controls. These findings support a unifying theory where
monocyte activity contributes to relief of ischemia in patients with PAD. While the exact
mechanism is unclear, it is plausible that increased circulating monocytes, recruited from the
bone marrow to ischemic areas via MCP-1, stimulate EPCs that subsequently contribute to
vascular healing.
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Statement of Purpose/Hypothesis/Specific Aims:

Monocytes may contribute to the healing process in patients with peripheral vascular disease.
Since ischemia appears to increase numbers of circulating monocytes, which in turn may
stimulate EPC activity, we hypothesize that ischemic areas secrete paracrine factors such as
MCP-1 to recruit bone marrow-derived monocytes into the circulation. These monocytes
may then recruit EPCs that participate in angiogenesis and resolution of ischemia. In patients
with critical limb ischemia requiring peripheral arterial bypass surgery, the relief of ischemia
by endogenous mechanisms is insufficient despite elevated levels of monocytes and
paracrine factors, possibly due to an impaired EPC response. We hypothesize that successful
surgical revascularization resolves ischemia and diminishes the stimulus for monocyte
recruitment, consequently decreasing the number of monocytes in the peripheral circulation.
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Methods:

The records of all consecutive lower extremity peripheral bypass surgery cases performed at
the VA Connecticut Healthcare Systems (West Haven, CT) between July 2002 and June
2007 were reviewed.

Patients were included in the study if they had a preoperative complete blood count (CBC)
with differential recorded within one year prior to bypass surgery as well as a postoperative
CBC with differential recorded between four months and 1.5 years after performance of the
bypass surgery. The primary study time frame is defined as the time bounded by the dates of
these lab tests.

Patients were excluded from the study if the surgery was a revision, in cases where staged
surgeries for bilateral lower extremities resulted in overlapping lab tests, and if the bypass
surgery was an inflow procedure (with target vessel proximal to the AK popliteal artery). In
addition, procedures complicated by limb-threatening graft failure within the study time
frame were excluded; for example, if graft thrombosis required graft revision or amputation,
or if persistent graft infection required graft removal or lifetime suppressive antibiotics.

Patient risk factors were determined by thorough chart review. Demographic variables
included the following: age, sex, diabetes, statin therapy, smoking status (never, prior, or
current smoker), and affected extremity (left or right). Operative data included the type of
graft (native or prosthetic) and the outflow vessel (AK popliteal, BK popliteal or tibial).
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Outcome variables included the following: graft status (patent or thrombosed), limb status
(intact or amputation), and mortality. Patient information with respect to the outcome
variables was gathered until the date of last patient contact, which extended beyond the
primary study time frame.

The primary dependent variable of interest in this study was the monocyte count ratio, which
was used to determine whether there was a change in monocyte count with any given risk
factor. Each cell count was derived from the CBC by multiplying the absolute white blood
cell (WBC) count by the percent of cells in the differential. Each cell ratio was calculated by
dividing the postoperative cell count by the preoperative cell count; a ratio greater than one
corresponds to an increase in circulating cells postoperatively, whereas a ratio less than one
corresponds to a decrease in circulating cells postoperatively.

Results are reported as mean ± SEM. Categorical variables were analyzed using Pearson’s
Chi-Square or the Fisher exact test. Continuous variables were analyzed using ANOVA.
Survival data was analyzed using Kaplan-Meier statistics, and the curves were compared
using the Log Rank (Mantel-Cox) test. The effect of multiple patient risk factors on the
dependent variable of interest was analyzed by multivariable logistic regression. All tests
were 2-tailed and p values ≤ 0.05 were considered statistically significant. (Statview 5.0,
SAS Institute, Cary, NC).
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Results:

Demographics
There were a total of 110 lower extremity peripheral bypass surgery cases performed at the
VA Connecticut Healthcare System between July 2002 and June 2007. A total of 32 cases
from the initial 110 charts reviewed met the inclusion, but not the exclusion, criteria and
were the subject of this study.

Three-fourths of our study population (n=24) had baseline critical limb ischemia (CLI;
Fontaine Stage III-IV), and presented with rest pain, chronic foot ulceration, and/or gangrene
requiring operative intervention. One-fourth of our study population (n=8) did not present
with signs of CLI, i.e. had no baseline ischemia, and were designated the control group. Half
of these patients (n=4) had bypass surgery for exclusion of asymptomatic popliteal aneurysm
and the other half (n=4) had surgery for relief of intermittent claudication (Fontaine Stage II).

The demographics of these patients are listed in Table 1. The mean age of CLI patients was
67.6 ± 1.7 years and the mean age of controls was 72.6 ± 5.1 years; there was no significant
difference in age between the two groups (p=0.242). All of the patients were men, as this
study was conducted within the VA system (Table 1).

Diabetes (n=10) was more prevalent in the group with CLI as compared to control patients
(41.7% vs. 0%; p=0.035). Smoking was also distributed unequally; of the patients who had
never smoked (n=3) none were in the CLI group (0% of CLI patients vs. 37.5% of controls;
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p=0.003). Of the patients who were prior smokers but had quit before the surgery (n=14)
there was little difference between groups (41.7% of CLI patients vs. 50% of controls); and
of the patients who were current smokers at the time of the surgery (n=15) the majority were
in the CLI group (58.3% of CLI patients vs. 12.5% of controls; p=0.003). There was no
significant difference between the two groups in terms of age, sex, statin therapy, type of
graft, outflow vessel, or operative extremity (Table 1).

Patients with CLI had increased preoperative monocyte counts compared to controls (0.753 ±
0.04 vs. 0.516 ± 0.05; p=0.0046) but there was no difference in preoperative lymphocyte
counts between patients with CLI and controls (1.979 ± 0.14 vs. 1.912 ± 0.22; p=0.814).
Patients with CLI also had elevated preoperative WBC counts (9.517 ± 0.56 vs. 7.225 ± 1.10;
p=0.055) and neutrophil counts (6.458 ± 0.53 vs. 4.612 ± 0.93; p=0.092) compared to control
patients, but these differences were not significant (Table 1).

Outcomes
Postoperative outcomes are presented in Table 2. Follow-up was complete in all patients;
however, the mean follow-up time was slightly shorter in patients with ischemia compared to
control patients (2.14 years vs. 3.26 years; p=0.042). Consistent with the study design, all
deaths and amputations occurred outside of the study time frame, which was defined as the
time bounded by the dates of the preoperative and postoperative CBC. Death prior to a
postoperative CBC would exclude the patient due to insufficient data, and amputation would
exclude the patient due to graft failure and unsuccessful resolution of limb ischemia at the
time of the postoperative CBC. Deaths (n=9) occurred only in CLI patients (37.5% vs. 0%;
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p=0.070) and amputations (n=4) also occurred only in CLI patients (16.7% vs. 0%; p=0.550).
These results are notable but not statistically significant (Table 2).

Thrombosed grafts were grouped by the date of occurrence (within or outside the study time
frame). Of the patients who had thrombosed grafts within the study time frame (n=4) none
were in the CLI group (16.7% of CLI patients vs. 0% of controls; p=0.550). After the study
time frame, the majority of patients who had thrombosed grafts (total n=9) were in the CLI
group (n=8 or 33.3% of CLI patients vs. n=1 or 12.5% of controls; p=0.386; Table 2).

The survival curves for mortality rate, amputation rate, and thrombosis rate are shown in
Figure 3. Survival data was analyzed using Kaplan-Meier statistics, and the curves were
compared using the Log Rank (Mantel-Cox) test. These curves demonstrate the percent of
patients in the CLI group and the control group who remained free of any given event (death,
amputation, or thrombosis) over time. Patients dropped out of the analysis either on the date
of last follow-up or on the date of the index event (Figure 3).

The mortality curve (Figure 3A) shows a significant difference between the groups. All
deaths (n=9) occurred in CLI patients within three years of the surgery. Approximately 91%
of the CLI patients were alive at one year, 73% at two years, and 47% at three years. This is
statistically significant compared to control patients, who had a 100% survival rate (p=0.032;
Figure 3A).
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The amputation curve (Figure 3B) shows no significant difference between groups. All
amputations (n=4) occurred in CLI patients within two years of the surgery. Approximately
92% of the CLI patients were intact at one year, and 76% at two years. These results are not
statistically significant despite the fact that control patients remained 100% intact (p=0.168;
Figure 3B).

The thrombosis curve (Figure 3C) shows no significant difference between groups. There
were a total of n=9 thrombotic events; n=8 in the CLI group and n=1 in the control group.
Thrombosis occurred within two years of the surgery. Approximately 83% of the CLI
patients had patent grafts at one year, and 58% at two years. All of the control patients had
patent grafts at one year, and 87.5% were patent at two years. These results are not
statistically significant (p=0.186; Figure 3C).

Monocyte Counts
The primary dependent variable of interest was the monocyte ratio, and on univariable
analysis only two risk factors had a significant effect on this ratio. The univariable analyses
are summarized in Table 3. This table shows that patients with preoperative CLI had
decreased monocyte counts after revascularization compared to control patients without
preoperative CLI (-20% vs. +55%; p=.0003). In addition, diabetic patients also had
significantly reduced postoperative monocyte counts compared to patients without diabetes
(-32% vs. +13%; p=0.035). Age greater than or less than 70, statin therapy, smoking status,
type of graft, outflow vessel, operative extremity, graft status, and mortality had no
significant effect on the postoperative monocyte count (Table 3).
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Since mononuclear cells are represented in the peripheral blood by both monocytes and
lymphocytes, we determined the effect of CLI on both the monocyte and the lymphocyte
counts. Figure 4 shows the effect of CLI on various peripheral blood cell populations. In
patients with CLI, the monocyte ratio decreased significantly after bypass surgery (-20% vs.
+55%; p=.0003; Figure 4A); however, the lymphocyte ratio was unchanged after
revascularization in both ischemic and control patients (-10% vs. +1%; p=0.404; Figure 4B).
In patients with CLI, both the WBC and neutrophil counts were also significantly decreased
after revascularization (Figure 4). The diminished WBC ratio in patients with CLI (-14% vs.
+26%; p=0.008; Figure 4C) paralleled the diminished neutrophil ratio (-9% vs. +39%;
p=0.037; Figure 4D).

To determine the significance of the risk factors identified by univariable analysis, we
performed multivariable logistic regression to identify which of these risk factors was
relevant (Table 4). Our results demonstrate that the only factor that independently predicts
reduced postoperative monocyte count is preoperative CLI (p=0.038). Age, thrombosed graft,
native graft, smoking status, diabetes, statin therapy, tibial outflow, and mortality do not
predict a diminished postoperative monocyte count (Table 4).
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Discussion:

We report two findings consistent with our hypothesis regarding patients with CLI
undergoing lower extremity peripheral bypass surgery. First, we report that the preoperative
monocyte count was elevated in patients with CLI compared to control patients with no
baseline critical ischemia. Second, we report that the monocyte count decreased significantly
after successful revascularization in patients with CLI compared to control patients. Diabetes
was also associated with a decreased monocyte count after peripheral bypass surgery;
however, using multivariable analysis, only CLI independently predicted a decreased
monocyte count after successful revascularization.

We believe that one of our most significant findings was that the preoperative monocyte
count was elevated in patients with CLI compared to control patients. Interestingly, the
difference was not apparent on the WBC differential, which only lists individual WBC
populations as percentages of the total WBC count. It is likely that the poor sensitivity for
differences in the low number of circulating monocytes resulted in a lack of significance
when percentages were compared. However, normalization to the absolute WBC count
revealed the greater preoperative absolute number of circulating monocytes in patients with
CLI (Table 1). This observation is consistent with our hypothesis that patients with baseline
CLI secrete paracrine factors such as MCP-1 to stimulate monocyte recruitment from the
bone marrow, promoting angiogenesis and resolution of ischemia. Notably, monocytes were
the only WBC component that had significantly different preoperative values when
comparing patients with CLI to control patients (p=0.0046; Table 1). These results also agree

59
with the report from Nasir and colleagues which demonstrated that elevated circulating
monocytes were the only WBC fraction that correlated significantly and independently with
the presence of PAD [86]. Further studies that quantify the severity of ischemia may lead to a
quantitative correlation between the magnitude of ischemia and the degree of elevation of the
preoperative monocyte count.

We believe that increased recruitment of monocytes in patients with CLI is intimately related
to recruitment of EPCs, and that circulating numbers of EPCs correlate inversely with the
severity of PAD. We propose that monocytes are recruited in parallel with EPCs, perhaps
via the same paracrine mechanism. This possibility is supported by the recent study by
Sieveking and colleagues, who isolated and defined two different populations of putative
EPCs, early endothelial progenitor cells (early EPCs) and late outgrowth endothelial cells
(late OECs) [87]. Early EPCs augment angiogenesis in a paracrine fashion, and have been
used in therapeutic studies [10,11,50]. In contrast, late OECs form colonies with high
proliferation rates, and are capable of forming vascular networks in vitro. This EPC and
monocyte lineage is represented in Figure 2. It has been proposed that early EPCs are not
true progenitors of endothelial cells but are actually monocytic cells capable of indirectly
facilitating angiogenesis in a paracrine fashion, while late OECs are the true EPCs [87].

Thus it is entirely possible that monocytic cells (called “early EPCs” by Sieveking, which
may not be progenitor cells, despite the nomenclature) stimulate true EPCs (called “late
OECs” by Sieveking) to respond to ischemia. This possibility correlates with our observation
that monocytes are increased in patients with ischemia and decreased after resolution of
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ischemia, since recruitment of EPCs depends on both monocytes and on the severity of
vascular injury.

Furthermore, in patients with CLI that is severe enough to require peripheral arterial bypass
surgery, endogenous mechanisms are necessarily insufficient to relieve the ischemia, despite
elevated levels of MNCs, monocytes, and other paracrine factors. This suggests that the
monocyte may not be the ultimate effector cell responsible for healing, and reinforces the
theory that the EPC is the effector cell. It is possible that elderly and chronically ill patients
with deficient reserves of EPCs may experience greater increases in monocytes in the setting
of ischemia due to ineffective EPC recruitment, failure of EPCs to repair vascular injury, or
other monocyte-EPC interactions. This theory explains the simultaneous existence of two
findings that seem contradictory: how elevated monocyte counts are present in patients with
CLI, despite the fact that monocytes participate in vascular healing and resolution of
ischemia.

The only two demographic variables that were significantly different in ischemic patients
compared to controls were diabetes and smoking. Diabetes was significantly more prevalent
in the group with CLI as compared to control patients, and smoking status was also
distributed unequally, with smokers being at greater risk for more severe disease. For these
variables, our results parallel the known risk factors for PAD and CLI with remarkable
accuracy [72].
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In addition, we also found that monocytes, but not lymphocytes, decreased in patients with
CLI after successful revascularization with a surgical bypass procedure (Figure 4A and 4B).
This decrease in monocytes after resolution of ischemia is consistent with our hypothesis that
monocytes recruit EPCs to promote healing in the setting of ischemia. These results are also
consistent with the report from Seidler and colleagues describing the angiogenesis response
to MCP-1 in ischemic tissue [85]. When resolution of ischemia is achieved, the demand for
active cell populations that target vessel healing is diminished, decreasing both circulating
MCP-1 and monocytes.

Importantly, the fact that the lymphocyte ratio did not change postoperatively in either the
CLI patients or the control patients strongly suggests that it is the monocyte fraction, not the
lymphocyte fraction, of the mononuclear cell population which is responsive to ischemia.

Notably, we measured the postoperative CBC at a minimum of four months after surgery to
minimize effects of transient postoperative changes associated with injury, inflammation, and
stress of the surgical procedure. Although we were limited to data obtained in a retrospective
format, and therefore had no control over the dates of test selection, we believe that the
random sampling of both preoperative and postoperative tests increases the power of
findings, as there is no test selection bias.

In addition to decreased postoperative monocyte count in patients with CLI, we found that
the postoperative WBC and neutrophil counts were also diminished in these patients (Figure
4C and 4D). Since neutrophils comprise approximately 85% of circulating WBCs, we
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believe that the diminished postoperative neutrophil count is primarily responsible for the
diminished WBC count. However, since neutrophils are not mononuclear cells, they cannot
account for the decrease in monocyte count. We speculate that the diminished WBC and
neutrophil counts in patients with successful limb revascularization reflects the resolution of
preoperative inflammation present in these critically ill patients. This is consistent with the
slightly elevated pre-operative WBC counts in patients with CLI, as well as elevated rates of
smoking and diabetes, compared to control patients (Table 1). In addition, we believe that
the increased inflammation in patients with CLI may account for their diminished long-term
survival (Figure 3A).

One distinct advantage of our control group is that it is composed of patients without baseline
ischemia who underwent peripheral bypass surgery. This is an unusual patient population,
since the vast majority of patients who undergo open limb revascularization procedures have
CLI. The incidental discovery of asymptomatic popliteal aneurysms (n=4 in our control
group) is also rare. In addition, surgery is not the first line treatment for patients with
claudication (n=4 in our control group), and is recommended only in patients whose
claudication interferes significantly with their activities or with their work. The advantage of
our control group is that it allows comparison of patients with no baseline ischemia to
patients with critical ischemia before and after the same intervention. We believe that the
small increases in monocyte, WBC, and neutrophil ratios in control patients (Figure 4) may
reflect natural variation in this small number of patients, and additional studies with larger
numbers of patients will clarify whether these increases are truly significant.
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A major limitation of this study is the small number of patients. This is primarily due to the
exclusion of large numbers of patients because they did not have a CBC with differential
performed as part of their perioperative laboratory studies. However, enough patients were
present for us to detect a decrease in postoperative monocyte count. Since laboratory tests
may be ordered more frequently for patients admitted to the hospital, selection of an
asymptomatic control group may be difficult in retrospective studies. In addition, our study
design selected control patients without limb-threatening graft failure, so our survival data
(Figure 3) was biased towards patients with better outcomes and is not generalizable to all
patients with limb revascularization in our institution; on the other hand, selection of patients
with patent grafts, or only mild graft failure, was necessary to determine whether relief of
ischemia influenced the monocyte count. Additional studies that are not retrospective must
be conducted to confirm the results of this study. In addition, further studies may allow
correlation of circulating cytokines and other factors to the level of ischemia and to the
circulating monocyte count.
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Conclusions:

Our retrospective study suggests that resolution of CLI after surgical revascularization results
in diminished numbers of circulating monocytes. We believe that this is due to the relief of
ischemia and a subsequent decrease in the demand for regenerative stem cells recruited from
the bone marrow. Our theory presupposes that the resolution of ischemia and associated
inflammation causes a concomitant decrease in circulating cytokines or growth factors,
resulting in decreased mobilization of stem cells and monocytes from the bone marrow.
However, the true effector cell remains unclear: of the mononuclear cell fraction, our results
strongly suggest a role for monocytes rather than lymphocytes. However, as EPCs are
thought to be a component of the monocyte population, it remains to be determined whether
the protective and healing effect is due to monocyte activity, EPC activity, or the activity of
both cell types. It is reasonable to conclude, however, that circulating monocytes may be a
clinically useful surrogate marker of circulating stem cells in patients with peripheral arterial
disease.
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Table 1: Demographic Variables
Variable
Total patients
Age (years)

Total Number Percent of Total
32

Control

Control (%)

8

Ischemic

Ischemic (%) P value

24

68.9 ± 1.8

-

72.6 ± 5.1

-

67.6 ± 1.7

-

0.2423

Male

32

100.0%

8

100.0%

24

100.0%

>0.9999

Female

0

0.0%

0

0.0%

0

0.0%

No

22

68.8%

8

100.0%

14

58.3%

Yes

10

31.3%

0

0.0%

10

41.7%

Sex

Diabetes
0.0353

Statin Therapy
No

12

37.5%

3

37.5%

9

37.5%

Yes

20

62.5%

5

62.5%

15

62.5%

> 0.9999

Smoking Status
Never a Smoker

3

9.4%

3

37.5%

0

0.0%

Prior Smoker

14

43.8%

4

50.0%

10

41.7%

Current Smoker

15

46.9%

1

12.5%

14

58.3%

0.0028

Type of Graft
19

59.4%

4

50.0%

15

62.5%

13

40.6%

4

50.0%

9

37.5%

AK Popliteal

10

31.3%

4

50.0%

6

25.0%

BK Popliteal

13

40.6%

4

50.0%

9

37.5%

Tibial

9

28.1%

0

0.0%

9

37.5%

Left

10

31.3%

1

12.5%

9

37.5%

Right

22

68.8%

7

87.5%

15

62.5%

Native Vein
Prosthetic

0.6838

Outflow Vessel
0.1091

Operative Extremity
0.3803

7.225 ± 1.10

9.517 ± 0.56

0.0554

Preoperative Lymphocyte Count

1.912 ± 0.22

1.979 ± 0.14

0.8143

Preoperative Neutrophil Count

4.612 ± 0.93

6.458 ± 0.53

0.0923

Preoperative Monocyte Count

0.516 ± 0.05

0.753 ± 0.04

0.0046

Preoperative Eosinophil Count

0.147 ± 0.03

0.254 ± 0.05

0.2627

Preoperative Basophil Count

0.032 ± 0.01

0.063 ± 0.01

0.1902

Preoperative WBC Count (cells per HPF)
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Table 2: Outcome Variables

Variable
Total patients
Mean Follow-Up Time (years)

Total Number Percent of Total

Control Control (%) Ischemic Ischemic (%) P value

32

8

24

2.42

3.26

2.14

0.0421

Mortality:
Alive

23

71.9%

8

100.0%

15

62.5%

Dead

9

28.1%

0

0.0%

9

37.5%

Intact

28

87.5%

8

100.0%

20

83.3%

AKA or BKA

4

12.5%

0

0.0%

4

16.7%

Patent

28

87.5%

8

100.0%

20

83.3%

Thrombosed

4

12.5%

0

0.0%

4

16.7%

23

71.9%

7

87.5%

16

66.7%

9

28.1%

1

12.5%

8

33.3%

0.0699

Limb Status:
0.5497

Graft Status:
Within study time frame

Through Follow-Up
Patent
Thrombosed

0.5497

0.3858
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Table 3: Univariable Analysis for
Factors Affecting Monocyte Ratio
Variable
Age (years)

Risk Factor

Mean Monocyte Ratio P-value

< 70
≥ 70

1.077
0.898

0.3726

Preoperative CLI

No
Yes

1.554
0.799

0.0003

Diabetes

No
Yes

1.127
0.682

0.0348

Statin Therapy

No
Yes

0.952
1.009

0.7858

Smoking Status

Never a Smoker
Prior Smoker
Current Smoker

1.182
1.063
0.878

0.5655

Type of Graft

Native Vein
Prosthetic

0.940
1.057

0.5693

Outflow Vessel

AK Popliteal
BK Popliteal
Tibial

1.192
1.071
0.641

0.0740

Left
Right

0.996
0.984

0.9552

Patent
Thrombosed

1.002
0.889

0.7126

Alive
Dead

1.088
0.732

0.1055

Operative Extremity

Graft Status
(within study time frame)
Mortality
(after study time frame)
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Table 4: Multivariable Logistic
Regression Analysis

Variable

P-Value

Exp (Coef)

95% Lower

95% Upper

Age
Thrombosed Graft
Native Graft
Preoperative CLI
Smoking Status
Diabetes
Statin Therapy
Tibial Outflow
Mortality

0.5506
0.1212
0.2664
0.0377
0.9155
0.6373
0.5023
0.9962
0.534

1.046
0.021
0.186
91.883
1.245
0.423
0.348
4.77E+08
0.317

0.903
1.62E-04
0.01
1.291
0.022
0.012
0.016
0
0.008

1.211
2.775
3.619
6538
71.239
15.169
7.596

∞
11.852
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Figure 1: Endothelial Cell Derivation Diagram
Multiple cell types are known to give rise to endothelial cells. Bold arrows show the pathway most
commonly cited. Adapted from Urbich [12] and colleagues. VE cadeherin = vascular endothelial
cadherin; VEGF-R2 = vascular endothelial growth factor receptor 2; vWF = von Willebrand factor.
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Figure 2: EPC and Monocyte Lineage Diagram
Bold arrows show the pathways most commonly cited. Dashed arrow shows the pathway for
paracrine stimulation. Adapted from Urbich [12] and Shantsila [89]. VE cadeherin = vascular
endothelial cadherin; VEGF-R2 = vascular endothelial growth factor receptor 2; vWF = von
Willebrand factor; early “EPC” = early endothelial progenitor cell, found to be a monocyte, not a
progenitor cell, by Sieveking and colleagues [87]; question mark on early “EPC” monocyte cell
membrane suggests specific markers are unknown; late outgrowth endothelial cell, found to be a true
endothelial progenitor cell by Sieveking and colleagues [87].
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Figure 3: Survival
FigureCurves
3: Survival Curves
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Figure 4: Effect of Critical Limb Ischemia
Figure
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